Barclays has reduced its price target for Kura Oncology (KURA) from $32 to $11 following the company's Q1 report, while maintaining an Overweight rating. Despite this adjustment, analysts remain optimistic, with a consensus average target of $28, suggesting a potential upside of 331.43% from the current price of $6.49. Kura has made significant strides, including submitting a New Drug Application for ziftomenib and achieving a $45 million milestone payment, while holding a robust cash position of $703.2 million to support its ongoing programs.